To our knowledge, this is the first study to report the presence of CD133+ in AT/RT, and to show that the activated p-ATM pathway and BCL-2-related antiapoptotic activity in CD133+ and IR-CD133+ render the CD133+ subpopulation capable of causing radio/chemoresistance in malignant tumors. Here, BCL2 is linked to cancer.